Cargando…

The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy

PURPOSE: To examine the validity of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) for the assessment of function in a community-based sample of patients with chronic pain conditions undergoing evaluation for chronic opioid therapy. PATIENTS AND METHODS: One hundred ni...

Descripción completa

Detalles Bibliográficos
Autores principales: Wawrzyniak, Kelly M, Finkelman, Matthew, Schatman, Michael E, Kulich, Ronald J, Weed, Valerie F, Myrta, Eura, DiBenedetto, David J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6573777/
https://www.ncbi.nlm.nih.gov/pubmed/31354334
http://dx.doi.org/10.2147/JPR.S207870
_version_ 1783427782415482880
author Wawrzyniak, Kelly M
Finkelman, Matthew
Schatman, Michael E
Kulich, Ronald J
Weed, Valerie F
Myrta, Eura
DiBenedetto, David J
author_facet Wawrzyniak, Kelly M
Finkelman, Matthew
Schatman, Michael E
Kulich, Ronald J
Weed, Valerie F
Myrta, Eura
DiBenedetto, David J
author_sort Wawrzyniak, Kelly M
collection PubMed
description PURPOSE: To examine the validity of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) for the assessment of function in a community-based sample of patients with chronic pain conditions undergoing evaluation for chronic opioid therapy. PATIENTS AND METHODS: One hundred nine of 124 patients were evaluated for a chronic opioid therapy program between December 1, 2014 and April 10, 2015, inclusive, at one community-based interdisciplinary pain management practice. Measures included: demographic data; the WHODAS 2.0; a modified version of the Roland Morris Disability Questionnaire (RMDQ-m); the Patient Health Questionnaire-9 item (PHQ-9); the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R); the Current Opioid Misuse Measure (COMM), the Opioid Risk Tool (ORT); opioid dose. These data were collected as part of routine care, and this retrospective chart review study examined the data from this convenience sample, comparing the results of each assessment tool to the results of the WHODAS 2.0. RESULTS: Median score on the WHODAS 2.0 was 25.69 (IQR=16.01 to 35.28). WHODAS 2.0 score was significantly correlated with the RMDQ-m (r(s)=0.69, p<0.001), the PHQ-9 (r(s)=0.68, p<0.001), the COMM (r(s)=0.52, p<0.001) and the SOAPP-R (r(s)=0.51, p<0.001). There was no significant correlation between the WHODAS 2.0 and the ORT (r(s)=0.14, p=0.12) or opioid dose (r(s)=0.07, p=0.47). CONCLUSIONS: The WHODAS 2.0 was significantly positively correlated with other measures, including measures of disability, risk of opioid misuse, and depression among patients being evaluated for chronic opioid therapy. The WHODAS 2.0 may be a useful measure of disability across a number of important domains when discussing expectations of both patients and providers at initiation of opioid therapy for chronic pain management. This assessment and discussion is crucial, particularly given the focus on function, rather than analgesia alone, when evaluating the effectiveness of opioid treatment.
format Online
Article
Text
id pubmed-6573777
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65737772019-07-26 The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy Wawrzyniak, Kelly M Finkelman, Matthew Schatman, Michael E Kulich, Ronald J Weed, Valerie F Myrta, Eura DiBenedetto, David J J Pain Res Original Research PURPOSE: To examine the validity of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) for the assessment of function in a community-based sample of patients with chronic pain conditions undergoing evaluation for chronic opioid therapy. PATIENTS AND METHODS: One hundred nine of 124 patients were evaluated for a chronic opioid therapy program between December 1, 2014 and April 10, 2015, inclusive, at one community-based interdisciplinary pain management practice. Measures included: demographic data; the WHODAS 2.0; a modified version of the Roland Morris Disability Questionnaire (RMDQ-m); the Patient Health Questionnaire-9 item (PHQ-9); the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R); the Current Opioid Misuse Measure (COMM), the Opioid Risk Tool (ORT); opioid dose. These data were collected as part of routine care, and this retrospective chart review study examined the data from this convenience sample, comparing the results of each assessment tool to the results of the WHODAS 2.0. RESULTS: Median score on the WHODAS 2.0 was 25.69 (IQR=16.01 to 35.28). WHODAS 2.0 score was significantly correlated with the RMDQ-m (r(s)=0.69, p<0.001), the PHQ-9 (r(s)=0.68, p<0.001), the COMM (r(s)=0.52, p<0.001) and the SOAPP-R (r(s)=0.51, p<0.001). There was no significant correlation between the WHODAS 2.0 and the ORT (r(s)=0.14, p=0.12) or opioid dose (r(s)=0.07, p=0.47). CONCLUSIONS: The WHODAS 2.0 was significantly positively correlated with other measures, including measures of disability, risk of opioid misuse, and depression among patients being evaluated for chronic opioid therapy. The WHODAS 2.0 may be a useful measure of disability across a number of important domains when discussing expectations of both patients and providers at initiation of opioid therapy for chronic pain management. This assessment and discussion is crucial, particularly given the focus on function, rather than analgesia alone, when evaluating the effectiveness of opioid treatment. Dove 2019-06-10 /pmc/articles/PMC6573777/ /pubmed/31354334 http://dx.doi.org/10.2147/JPR.S207870 Text en © 2019 Wawrzyniak et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wawrzyniak, Kelly M
Finkelman, Matthew
Schatman, Michael E
Kulich, Ronald J
Weed, Valerie F
Myrta, Eura
DiBenedetto, David J
The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy
title The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy
title_full The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy
title_fullStr The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy
title_full_unstemmed The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy
title_short The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy
title_sort world health organization disability assessment schedule-2.0 (whodas 2.0) in a chronic pain population being considered for chronic opioid therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6573777/
https://www.ncbi.nlm.nih.gov/pubmed/31354334
http://dx.doi.org/10.2147/JPR.S207870
work_keys_str_mv AT wawrzyniakkellym theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy
AT finkelmanmatthew theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy
AT schatmanmichaele theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy
AT kulichronaldj theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy
AT weedvalerief theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy
AT myrtaeura theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy
AT dibenedettodavidj theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy
AT wawrzyniakkellym worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy
AT finkelmanmatthew worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy
AT schatmanmichaele worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy
AT kulichronaldj worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy
AT weedvalerief worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy
AT myrtaeura worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy
AT dibenedettodavidj worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy